{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-082875","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2026-07-13T11:39:07+00:00","discovered_at":"2026-07-13T11:40:00.303859+00:00","generated_at":"2026-07-13T11:40:04.748609+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Alto Neuroscience reports ~$244.2M cash; plans additional Phase 3 trial for ALTO-207","bullets":["Preliminary cash, cash equivalents and restricted cash of ~$244.2M as of June 30, 2026 (unaudited).","Company intends to accelerate ALTO-207 development, including an additional Phase 3 monotherapy trial for treatment-resistant depression.","No other financial results or guidance provided in this filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-082875","json":"https://secwatch.observer/filing/0001104659-26-082875.json","markdown":"https://secwatch.observer/filing/0001104659-26-082875.md","text":"https://secwatch.observer/filing/0001104659-26-082875.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926082875/0001104659-26-082875-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000110465926082875/tm2620297d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-13T11:40:04.748609+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}